CYP3A4~*1G多态性对芬太尼术后静脉镇痛效应的影响
摘要
【背景与目的】
在我国芬太尼是常用的阿片类术后静脉镇痛药物,临床资料表明不同个体间术后镇痛芬太尼的需求量和不良反应存在显著差异。研究证实芬太尼静脉给药后主要在肝脏内通过细胞色素P450(cytochrome P450,CYP)3A4酶代谢成为无活性产物,CYP3A4酶活性在不同个体存在明显差异,且编码CYP3A4酶的基因存在多态性。研究提示CYP3A4基因多态性可能是造成不同个体药物代谢差异的基础。CYP3A4~*1G是目前已发现的中国人所有的CYP3A4单核苷酸多态性中发生频率最高的一个位点。研究提示该基因多态性可能影响其表型即CYP3A4酶活性,但结论不一。CYP3A4~*1G多态性是否会引起酶活性的改变,间接造成术后芬太尼静脉镇痛需要量的差异,尚不可知。本研究旨在通过分析CYP3A4~*1G多态性和CYP3A4酶活性,探讨妇科患者全麻术后芬太尼静脉自控镇痛效应个体差异的遗传因素,为临床制订芬太尼术后镇痛的个体化用药方案提供理论依据。
【材料与方法】
1.研究对象与分组
190例妇科择期全麻下腹式子宫肌瘤剔除术或子宫全切术患者,ASAⅠ或Ⅱ级,年龄20-50岁,体重指数在正常范围(1±20%),拟行术后静脉镇痛者。排除有严重心血管疾病、糖尿病、严重肝脏病、肾脏病史,吸烟、酗酒史,慢性疼痛史、长期使用镇痛药物的患者,处于孕期或哺乳期的患者,并排除术前1个月内服用过对肝脏CYP3A4酶有诱导或抑制作用的药物或食物的患者。根据CYP3A4~*1G基因型检测结果将患者分为CYP3A4~*1/~*1(野生型纯合子)、CYP3A4~*1/~*1G(突变型杂合子)和CYP3A4~*1G/~*1G(突变型纯合子)三组。
2.麻醉与镇痛
研究设计得到医院伦理委员会同意,所有患者签署知情同意书后进入试验。术中采用统一的全凭静脉麻醉方法,麻醉诱导静脉注射咪达哗仑(MDZ)、异丙酚、瑞芬太尼和琥珀酰胆碱;静脉输注异丙酚和瑞芬太尼,间断静脉注射阿曲库铵维持麻醉;手术结束时停用所有麻醉药物,待患者自主呼吸恢复满意,神志清醒后拔除气管导管,采用视觉模拟评分(visual analog scale,VAS)评定术后即刻疼痛程度并记录,接电子镇痛泵行静脉芬太尼病人自控镇痛(patient-controlled intravenous analgesia,PCIA)。镇痛泵内药物配方为芬太尼1.0 mg、氟哌利多5 mg,加生理盐水至100 ml。PCIA设置:芬太尼背景剂量5μg/h、追加剂量20μg/次、锁定时间5 min、最大限量145μg/h。活动时疼痛VAS评分≤3分定义为有效镇痛,若已达到每小时最大剂量VAS评分仍＞3分,则辅用其他镇痛药物。观察并记录术后即刻和每个24h内芬太尼消耗量、平均VAS评分以及不良反应发生情况。
3.基因多态性检测
采用酚-氯仿法提取外周静脉血DNA,聚合酶链反应-限制性片段长度多态性分析(polymerase chain reaction-restriction fragment length polymorphism,PCR-RFLP)技术检测CYP3A4~*1G基因型,并通过PCR扩增产物基因测序以验证基因分型方法的可靠性。
4.CYP3A4酶活性检测
采用MDZ作为探针药物,麻醉诱导静脉注射MDZ1 h时抽取外周静脉血5 ml,液相色谱-质谱检测法(LC-MS)测定血浆中MDZ及其代谢产物1′-OH MDZ浓度。以1′-OH MDZ与MDZ比值作为CYP3A4酶活性的指标。
5.统计学分析
数据采用SPSS11.0软件进行分析,计量资料以(?)±s表示,以x~2检验检测等位基因和基因型分布是否符合Hardy-Weinberg平衡;x~2检验或Fisher's精确概率检验比较不同种族间等位基因的发生频率;多组间数据进行单因素方差分析(ANOVA),各组间比较采用LSD法。组间芬太尼消耗量的比较采用协方差分析以排除混杂因素影响。不良反应发生率的比较采用x~2检验或Fisher's精确概率法。突变等位基因数量与芬太尼消耗量之间的相关性采用等级相关分析,计量资料变量之间的关系采用直线相关分析。检验水准为α=0.05。
【结果】
1.一般情况
190例女性患者中,术后即刻VAS评分较高(5.7±1.4),术后第1个24 h平均VAS评分为2.2±0.8分;术后第2个24 h平均VAS评分为1.3±0.4,均达到有效镇痛。术后第1个24h芬太尼消耗量为391.5±201.7μg;第2个24h芬太尼消耗量为191.2±43.5μg。使用芬太尼镇痛时术后恶心呕吐的发生率为28.9%;轻度镇静的发生率为1.6%;瘙痒的发生率为0.5%;未见其他不良反应。
2.妇科患者中CYP3A4~*1G等位基因频率
CYP3A4~*1G等位基因在中国汉族妇科手术患者中的变异频率为29.7%,等位基因和基因型分布符合Hardy-Weinberg平衡(P＞0.05)。CYP3A4~*1G等位基因频率与日本人(24.9%)和中国高脂血症患者(27.6%)相近(P＞0.05)。
3.CYP3A4~*1G多态性对妇科患者CYP3A酶活性和术后芬太尼镇痛效应的影响
CYP3A4~*1/~*1、CYP3A4~*1/~*1G和CYP3A4~*1G/~*1G三组间一般情况比较差异无统计学意义(P＞0.05);术后即刻及术后24 h平均VAS评分组间差异无统计学意义(P＞0.05)。术后24 h芬太尼消耗量三组间差异有统计学意义(P＜0.05),CYP3A4~*1G/~*1G组(260.0±101.1μg)低于CYP3A4~*1/~*1组(406.7±186.6μg)和CYP3A4~*1/~*1G组(396.8±222.6μg);术后24 h芬太尼消耗量与患者携带CYP3A4~*1G等位基因数量呈负相关(r=-0.14,P＜0.05)。三组间CYP3A4酶活性的比较差异有统计学意义(P＜0.05),CYP3A4~*1G/~*1G组(0.34±0.15)低于CYP3A4~*1/~*1G组(0.46±0.12)和CYP3A4~*1/~*1组(0.46±0.14)。三组间术后镇痛期间不良反应发生率的比较差异无统计学意义(P＞0.05)。
【结论】
1.中国汉族妇科手术患者中CYP3A4~*1G等位基因的变异频率为29.7%;
2.CYP3A4~*1G是一个具有功能意义的突变,与CYP3A4酶活性和术后24 h芬太尼静脉镇痛消耗量降低有关。
Background and Objective
Fentanyl is a synthetic opioid that has been widely used in clinical practice and it is especially effective for induction and maintenance of anesthesia or control of analgesia.However,the effective dose of fentanyl for pain control varies greatly among individuals.Fentanyl is metabolized in the liver predominantly by the cytochrome P450 3A4(CYP3A4).CYP3A4 protein expression in the liver may vary up to 40-fold,leading to variations in drug metabolism and contributing to differences in individual response to the drug.Genetic variation within the CYP3A4 gene may contribute to interindividual variability in drug metabolism.Single nucleotide polymorphisms(SNPs) are the most common form of genetic variation in the CYP3A4.CYP3A4~*1G is a high-frequency allele in Chinese,the alteration of function remains unclear in vitro and in vivo.The influence of CYP3A4~*1G on fentanyl analgesic effect has not been reported.Due to the importance of CYP3A4 in the metabolism of fentanyl,we conducted this study to observe the impact of CYP3A4~*1G polymorphism on fentanyl effect for intravenous analgesia.The present study provides an important foundation and theoretical evidence for individualization of medication in the pain treatment.
Materials and Methods
1.Subjects
Total one hundred and ninety patients,having an American Society of Anesthesiologists(ASA) physical status ofⅠorⅡ,aged 20-50 yr,within±20%of ideal body weight,who were admitted into our medical institution for elective abdominal total hysterectomy or myomectomy,were enrolled in the current study. Patients with a known history of significant cardiovascular disease,diabetes mellitus, alcohol or drug abuse,hepatic or renal dysfunction,pregnancy or nursing,and chronic analgesic use were excluded from the study.Patients who had consumed drugs known to inhibit or induce the expression of CYP3A4 enzymes one month prior to surgery were also excluded.The patients were divided into three groups according to the genotypes.
2.Anesthetic Technique and Analgesia
All patients gave written informed consent for participating in the study and the study protocol was approved by the Institution Review Board at Zhengzhou University.A standardized general anesthesia protocol was used for all patients.We administered 0.1mg/kg midazolam,0.5 mg/kg propofol,2μg/kg remifentanil and 1 mg/kg succinylcholine for induction of anesthesia.Atracurium 0.6 mg/kg was administered intravenously as an initial dosage immediately after tracheal intubation was confirmed and then 0.1 to 0.2 mg/kg was administered by repeated boluses and 0.1 to 0.2μg/kg/min remifentanil and 6 to 8 mg/kg/h propofol were infused for maintenance of anesthesia.Postoperative PCA(1 mg fentanyl and 5 mg droperidol in 100 ml normal saline) was administered using a computer controlled infusion pump (CADD-Legacy 6300) which was programmed to give a 2 ml bolus of fentanyl solution with a 5 min lockout time,0.5 ml/h background infusion and a maximum of 145μg per hour.All patients received intravenous PCA with fentanyl once they were stable and awake.The delivered dose of fentanyl was recorded.VAS was used for assessing pain at rest during PCA.Successful analgesia was defined as a VAS score≤3.The VAS score and incidence of any adverse effects such as nausea,vomiting, respiratory depression and sedation were recorded.
3.Genotyping assays
Venous blood samples were collected from all patients.DNA was extracted using a standard phenol/chloroform procedure.Genotyping of CYP3A4~*1G allele was conducted by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).The results for each genotype were confirmed in randomly selected individuals by direct sequence analysis.
4.Evaluation of CYP3A4 activity
Peripheral blood sample(5 ml) was collected from each patient.CYP3A4 activity was measured by determining the plasma ratio of 1'-hydroxymidazolam to midazolam 1 h after intravenous administration of 0.1 mg/kg midazolam for induction of anesthesia.Midazolam and 1'-hydroxymidazolam concentrations were determined using a liquid chromatography-mass spectrometry.
5.Statistical analysis
SPSS 11.0 software was used for statistical analyses.Values were reported as (?)+s.The allele frequencies were estimated from the observed numbers of each specific allele.Chi-square test was used to verify Hardy-Weinberg equilibrium. One-way analysis of variance was used to assess whether significant differences exist between the three genotypes.Data for the fentanyl consumption were compared using one-way analysis of variance with post hoc Bonferroni correction,multiple comparisons was performed before and after adjusted for age,weight of the patients and remifentanil consumption in the operation.The incidences of any adverse effects were analyzed using Chi-square test or Fisher exact test.A two tailed P-value of＜0.05 was considered statistically significant.
Results
1.General information
Among the 190 patients,the VAS pain score immediately postoperatively was 5.7±1.4.At 24 h after surgery,it was 2.2±0.8.No one needed rescue management for inadequate pain control.The fentanyl consumption was 391.5±201.7μg and 191.2±43.5μg in the first and second 24 h postoperatively,respectively.The incidence of postoperative nausea and vomiting was 28.9%.The incidence of mild sedation and pruritus in our study was 1.6%and 0.5%,respectively.
2.Frequency of CYP3A4~*1G allele
The frequency of CYP3A4~*1G allele in gynecologic patients was 29.7%.The allele frequency was in Hardy-Weinberg equilibrium(P＞0.05).The allelic frequency of CYP3A4~*1G in our study was similar to that reported in Japanese(24.9%) and Chinese hyperlipidemic patients(27.6%)(P＞0.05).
3.Association of CYP3A4~*1G gene polymorphism with CYP3A4 activity and fentanyl analgesic effect
There were no significant differences in general information among the three genotype groups(P＞0.05).No statistical difference in postoperative VAS pain scores was detected across genotypes.The subjects with the CYP3A4~*1G/~*1G genotype (260.0±101.1μg) need less fentanyl to achieve pain control than subjects carrying the CYP3A4~*1/*1(406.7±186.6μg) and CYP3A4~*1/~*1G(396.8±222.6μg) genotypes (P＜0.05).Fentanyl consumption increased in accordance with the number of ~*1G alleles(r=-0.14,P＜0.05 for linear trend).The activity of CYP3A4 in ~*1G/~*1G group(0.34±0.15) was lower than in ~*1/~*1(0.46±0.14) and ~*1/~*1G(0.46±0.12) groups(P＜0.05).There was no significant difference in incidences of adverse events among the different genotype groups(P＞0.05).
Conclusions
1.The frequency of CYP3A4~*1G allele in Chinese gynecologic patients is 29.7%.
2.Carrying CYP3A4~*1G decrease the activity of CYP3A4 and patient-controlled intravenous fentanyl consumption.
在我国芬太尼是常用的阿片类术后静脉镇痛药物,临床资料表明不同个体间术后镇痛芬太尼的需求量和不良反应存在显著差异。研究证实芬太尼静脉给药后主要在肝脏内通过细胞色素P450(cytochrome P450,CYP)3A4酶代谢成为无活性产物,CYP3A4酶活性在不同个体存在明显差异,且编码CYP3A4酶的基因存在多态性。研究提示CYP3A4基因多态性可能是造成不同个体药物代谢差异的基础。CYP3A4~*1G是目前已发现的中国人所有的CYP3A4单核苷酸多态性中发生频率最高的一个位点。研究提示该基因多态性可能影响其表型即CYP3A4酶活性,但结论不一。CYP3A4~*1G多态性是否会引起酶活性的改变,间接造成术后芬太尼静脉镇痛需要量的差异,尚不可知。本研究旨在通过分析CYP3A4~*1G多态性和CYP3A4酶活性,探讨妇科患者全麻术后芬太尼静脉自控镇痛效应个体差异的遗传因素,为临床制订芬太尼术后镇痛的个体化用药方案提供理论依据。
【材料与方法】
1.研究对象与分组
190例妇科择期全麻下腹式子宫肌瘤剔除术或子宫全切术患者,ASAⅠ或Ⅱ级,年龄20-50岁,体重指数在正常范围(1±20%),拟行术后静脉镇痛者。排除有严重心血管疾病、糖尿病、严重肝脏病、肾脏病史,吸烟、酗酒史,慢性疼痛史、长期使用镇痛药物的患者,处于孕期或哺乳期的患者,并排除术前1个月内服用过对肝脏CYP3A4酶有诱导或抑制作用的药物或食物的患者。根据CYP3A4~*1G基因型检测结果将患者分为CYP3A4~*1/~*1(野生型纯合子)、CYP3A4~*1/~*1G(突变型杂合子)和CYP3A4~*1G/~*1G(突变型纯合子)三组。
2.麻醉与镇痛
研究设计得到医院伦理委员会同意,所有患者签署知情同意书后进入试验。术中采用统一的全凭静脉麻醉方法,麻醉诱导静脉注射咪达哗仑(MDZ)、异丙酚、瑞芬太尼和琥珀酰胆碱;静脉输注异丙酚和瑞芬太尼,间断静脉注射阿曲库铵维持麻醉;手术结束时停用所有麻醉药物,待患者自主呼吸恢复满意,神志清醒后拔除气管导管,采用视觉模拟评分(visual analog scale,VAS)评定术后即刻疼痛程度并记录,接电子镇痛泵行静脉芬太尼病人自控镇痛(patient-controlled intravenous analgesia,PCIA)。镇痛泵内药物配方为芬太尼1.0 mg、氟哌利多5 mg,加生理盐水至100 ml。PCIA设置:芬太尼背景剂量5μg/h、追加剂量20μg/次、锁定时间5 min、最大限量145μg/h。活动时疼痛VAS评分≤3分定义为有效镇痛,若已达到每小时最大剂量VAS评分仍＞3分,则辅用其他镇痛药物。观察并记录术后即刻和每个24h内芬太尼消耗量、平均VAS评分以及不良反应发生情况。
3.基因多态性检测
采用酚-氯仿法提取外周静脉血DNA,聚合酶链反应-限制性片段长度多态性分析(polymerase chain reaction-restriction fragment length polymorphism,PCR-RFLP)技术检测CYP3A4~*1G基因型,并通过PCR扩增产物基因测序以验证基因分型方法的可靠性。
4.CYP3A4酶活性检测
采用MDZ作为探针药物,麻醉诱导静脉注射MDZ1 h时抽取外周静脉血5 ml,液相色谱-质谱检测法(LC-MS)测定血浆中MDZ及其代谢产物1′-OH MDZ浓度。以1′-OH MDZ与MDZ比值作为CYP3A4酶活性的指标。
5.统计学分析
数据采用SPSS11.0软件进行分析,计量资料以(?)±s表示,以x~2检验检测等位基因和基因型分布是否符合Hardy-Weinberg平衡;x~2检验或Fisher's精确概率检验比较不同种族间等位基因的发生频率;多组间数据进行单因素方差分析(ANOVA),各组间比较采用LSD法。组间芬太尼消耗量的比较采用协方差分析以排除混杂因素影响。不良反应发生率的比较采用x~2检验或Fisher's精确概率法。突变等位基因数量与芬太尼消耗量之间的相关性采用等级相关分析,计量资料变量之间的关系采用直线相关分析。检验水准为α=0.05。
【结果】
1.一般情况
190例女性患者中,术后即刻VAS评分较高(5.7±1.4),术后第1个24 h平均VAS评分为2.2±0.8分;术后第2个24 h平均VAS评分为1.3±0.4,均达到有效镇痛。术后第1个24h芬太尼消耗量为391.5±201.7μg;第2个24h芬太尼消耗量为191.2±43.5μg。使用芬太尼镇痛时术后恶心呕吐的发生率为28.9%;轻度镇静的发生率为1.6%;瘙痒的发生率为0.5%;未见其他不良反应。
2.妇科患者中CYP3A4~*1G等位基因频率
CYP3A4~*1G等位基因在中国汉族妇科手术患者中的变异频率为29.7%,等位基因和基因型分布符合Hardy-Weinberg平衡(P＞0.05)。CYP3A4~*1G等位基因频率与日本人(24.9%)和中国高脂血症患者(27.6%)相近(P＞0.05)。
3.CYP3A4~*1G多态性对妇科患者CYP3A酶活性和术后芬太尼镇痛效应的影响
CYP3A4~*1/~*1、CYP3A4~*1/~*1G和CYP3A4~*1G/~*1G三组间一般情况比较差异无统计学意义(P＞0.05);术后即刻及术后24 h平均VAS评分组间差异无统计学意义(P＞0.05)。术后24 h芬太尼消耗量三组间差异有统计学意义(P＜0.05),CYP3A4~*1G/~*1G组(260.0±101.1μg)低于CYP3A4~*1/~*1组(406.7±186.6μg)和CYP3A4~*1/~*1G组(396.8±222.6μg);术后24 h芬太尼消耗量与患者携带CYP3A4~*1G等位基因数量呈负相关(r=-0.14,P＜0.05)。三组间CYP3A4酶活性的比较差异有统计学意义(P＜0.05),CYP3A4~*1G/~*1G组(0.34±0.15)低于CYP3A4~*1/~*1G组(0.46±0.12)和CYP3A4~*1/~*1组(0.46±0.14)。三组间术后镇痛期间不良反应发生率的比较差异无统计学意义(P＞0.05)。
【结论】
1.中国汉族妇科手术患者中CYP3A4~*1G等位基因的变异频率为29.7%;
2.CYP3A4~*1G是一个具有功能意义的突变,与CYP3A4酶活性和术后24 h芬太尼静脉镇痛消耗量降低有关。
Background and Objective
Fentanyl is a synthetic opioid that has been widely used in clinical practice and it is especially effective for induction and maintenance of anesthesia or control of analgesia.However,the effective dose of fentanyl for pain control varies greatly among individuals.Fentanyl is metabolized in the liver predominantly by the cytochrome P450 3A4(CYP3A4).CYP3A4 protein expression in the liver may vary up to 40-fold,leading to variations in drug metabolism and contributing to differences in individual response to the drug.Genetic variation within the CYP3A4 gene may contribute to interindividual variability in drug metabolism.Single nucleotide polymorphisms(SNPs) are the most common form of genetic variation in the CYP3A4.CYP3A4~*1G is a high-frequency allele in Chinese,the alteration of function remains unclear in vitro and in vivo.The influence of CYP3A4~*1G on fentanyl analgesic effect has not been reported.Due to the importance of CYP3A4 in the metabolism of fentanyl,we conducted this study to observe the impact of CYP3A4~*1G polymorphism on fentanyl effect for intravenous analgesia.The present study provides an important foundation and theoretical evidence for individualization of medication in the pain treatment.
Materials and Methods
1.Subjects
Total one hundred and ninety patients,having an American Society of Anesthesiologists(ASA) physical status ofⅠorⅡ,aged 20-50 yr,within±20%of ideal body weight,who were admitted into our medical institution for elective abdominal total hysterectomy or myomectomy,were enrolled in the current study. Patients with a known history of significant cardiovascular disease,diabetes mellitus, alcohol or drug abuse,hepatic or renal dysfunction,pregnancy or nursing,and chronic analgesic use were excluded from the study.Patients who had consumed drugs known to inhibit or induce the expression of CYP3A4 enzymes one month prior to surgery were also excluded.The patients were divided into three groups according to the genotypes.
2.Anesthetic Technique and Analgesia
All patients gave written informed consent for participating in the study and the study protocol was approved by the Institution Review Board at Zhengzhou University.A standardized general anesthesia protocol was used for all patients.We administered 0.1mg/kg midazolam,0.5 mg/kg propofol,2μg/kg remifentanil and 1 mg/kg succinylcholine for induction of anesthesia.Atracurium 0.6 mg/kg was administered intravenously as an initial dosage immediately after tracheal intubation was confirmed and then 0.1 to 0.2 mg/kg was administered by repeated boluses and 0.1 to 0.2μg/kg/min remifentanil and 6 to 8 mg/kg/h propofol were infused for maintenance of anesthesia.Postoperative PCA(1 mg fentanyl and 5 mg droperidol in 100 ml normal saline) was administered using a computer controlled infusion pump (CADD-Legacy 6300) which was programmed to give a 2 ml bolus of fentanyl solution with a 5 min lockout time,0.5 ml/h background infusion and a maximum of 145μg per hour.All patients received intravenous PCA with fentanyl once they were stable and awake.The delivered dose of fentanyl was recorded.VAS was used for assessing pain at rest during PCA.Successful analgesia was defined as a VAS score≤3.The VAS score and incidence of any adverse effects such as nausea,vomiting, respiratory depression and sedation were recorded.
3.Genotyping assays
Venous blood samples were collected from all patients.DNA was extracted using a standard phenol/chloroform procedure.Genotyping of CYP3A4~*1G allele was conducted by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).The results for each genotype were confirmed in randomly selected individuals by direct sequence analysis.
4.Evaluation of CYP3A4 activity
Peripheral blood sample(5 ml) was collected from each patient.CYP3A4 activity was measured by determining the plasma ratio of 1'-hydroxymidazolam to midazolam 1 h after intravenous administration of 0.1 mg/kg midazolam for induction of anesthesia.Midazolam and 1'-hydroxymidazolam concentrations were determined using a liquid chromatography-mass spectrometry.
5.Statistical analysis
SPSS 11.0 software was used for statistical analyses.Values were reported as (?)+s.The allele frequencies were estimated from the observed numbers of each specific allele.Chi-square test was used to verify Hardy-Weinberg equilibrium. One-way analysis of variance was used to assess whether significant differences exist between the three genotypes.Data for the fentanyl consumption were compared using one-way analysis of variance with post hoc Bonferroni correction,multiple comparisons was performed before and after adjusted for age,weight of the patients and remifentanil consumption in the operation.The incidences of any adverse effects were analyzed using Chi-square test or Fisher exact test.A two tailed P-value of＜0.05 was considered statistically significant.
Results
1.General information
Among the 190 patients,the VAS pain score immediately postoperatively was 5.7±1.4.At 24 h after surgery,it was 2.2±0.8.No one needed rescue management for inadequate pain control.The fentanyl consumption was 391.5±201.7μg and 191.2±43.5μg in the first and second 24 h postoperatively,respectively.The incidence of postoperative nausea and vomiting was 28.9%.The incidence of mild sedation and pruritus in our study was 1.6%and 0.5%,respectively.
2.Frequency of CYP3A4~*1G allele
The frequency of CYP3A4~*1G allele in gynecologic patients was 29.7%.The allele frequency was in Hardy-Weinberg equilibrium(P＞0.05).The allelic frequency of CYP3A4~*1G in our study was similar to that reported in Japanese(24.9%) and Chinese hyperlipidemic patients(27.6%)(P＞0.05).
3.Association of CYP3A4~*1G gene polymorphism with CYP3A4 activity and fentanyl analgesic effect
There were no significant differences in general information among the three genotype groups(P＞0.05).No statistical difference in postoperative VAS pain scores was detected across genotypes.The subjects with the CYP3A4~*1G/~*1G genotype (260.0±101.1μg) need less fentanyl to achieve pain control than subjects carrying the CYP3A4~*1/*1(406.7±186.6μg) and CYP3A4~*1/~*1G(396.8±222.6μg) genotypes (P＜0.05).Fentanyl consumption increased in accordance with the number of ~*1G alleles(r=-0.14,P＜0.05 for linear trend).The activity of CYP3A4 in ~*1G/~*1G group(0.34±0.15) was lower than in ~*1/~*1(0.46±0.14) and ~*1/~*1G(0.46±0.12) groups(P＜0.05).There was no significant difference in incidences of adverse events among the different genotype groups(P＞0.05).
Conclusions
1.The frequency of CYP3A4~*1G allele in Chinese gynecologic patients is 29.7%.
2.Carrying CYP3A4~*1G decrease the activity of CYP3A4 and patient-controlled intravenous fentanyl consumption.
引文
1. Victoria G. Pain care. Nurse Care North American 1994, 29(3):534-544.
2. Apfelbaum JL, Chen C, Mehta SS, et al. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg 2003, 97(2):534-540.
3. Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management: I. Evidence from published data. Br J Anaesth 2002, 89(3):409-423.
4. Bisgaard T, Klarskov B, Rosenberg J, et al. Characteristics and prediction of early pain after laparoscopic cholecystectomy. Pain 2001, 90(3):261-269.
5. Cepeda MS, Carr DB. Women experience more pain and require more morphine than men to achieve a similar degree of analgesia. Anesth Analg 2003, 97(5): 1464-1468.
6. Tan EC, Lim Y, Teo YY, et al. Ethnic differences in pain perception and patient-controlled analgesia usage for postoperative pain. J Pain 2008, 9(9):849-855.
7. Lotsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005, 11(2):82-89.
8. Nagashima M, Katoh R, Sato Y, et al. Is there genetic polymorphism evidence for individual human sensitivity to opiates? Curr Pain Headache Rep 2007, 11(2):115-123.
9. Abood ME. Molecular biology of cannabinoid receptors. Handb Exp Pharmacol 2005, (168):81-115.
10. Samer CF, Piguet V, Dayer P, et al. Genetic polymorphism and drug interactions: their importance in the treatment of pain. Can J Anaesth 2005, 52(8):806-821.
11. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P4503A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997,25(9):1072-1080.
12.舒炎,周宏灏.细胞色素P450药物氧化代谢酶的遗传药理学进展.见:王永铭,苏定冯,主编.药理学进展.第1版.北京:科学出版社,2000.19.
13.Zhu B,Liu ZQ,Chen GL,et al.The distribution and gender difference of CYP3A activity in Chinese subjects.Br J Clin Pharmacol 2003,55(3):264-269.
14.Ozdemir V,Kalow W,Tang BK,et al.Evaluation of the genetic component of variability in CYP3A4 activity:a repeated drug administration method.Pharmacogenetics 2000,10(5):373-388.
15.Hsieh KP,Lin YY,Cheng CL,et al.Novel mutations of CYP3A4 in Chinese.Drug Metab Dispos 2001,29(3):268-273.
16.Dai D,Tang J,Rose R,et al.Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.J Pharmacol Exp Ther 2001,299(3):825-831.
17.Du J,Xing Q,Xu L,et al.Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.Pharmacogenomics 2006,7(6):831-841
18.Du J,Yu L,Wang L,et al.Differences in CYP3A4~*1G genotype distribution and haplotypes of CYP3A4,CYP3A5 and CYP3A7 in 3 Chinese populations.Clin Chim Acta 2007,383(1-2):172-174.
19.Hu YF,Tu JH,Tan ZR,et al.Association of CYP3A4~*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects.Xenobiotica 2007,37(3):315-327.
20.Gao Y,Zhang LR,Fu Q.CYP3A4~*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.Eur J Clin Pharmacol 2008,64(9):877-882.
21.Kharasch ED,Thummel KE,Watkins PB.CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition.Mol Interv 2005,5(2):151-153.
22.Camu F,Van Aken H,Bovill JG,et al.Postoperative analgesic effects of three demand-dose sizes of fentanyl administered by patient-controlled analgesia.Anesth Analg 1998,87(4):890-895.
23.Sommer M,de Rijke JM,van Kleef M,et al.The prevalence of postoperative pain in a sample of 1490 surgical inpatients.Eur J Anaesthesiol 2008,25(4):267-274.
24.朱学慧,娄建石.细胞色素P4503A选择性探针药物的评价.中国临床药理学与治疗学.2004,9(4):365-369.
25.Lown KS,Kolars JC,Thummel KE,et al.Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel.Lack of prediction by the erythromycin breath test.Drug Metab Dispos 1994,22(6):947-955.
26.Thummel KE,Shen DD,Podoll TD,et al.Use of midazolam as a human cytochromeP4503Aprobe:Ⅰ.In vitro-in vivo correlations in liver transplant patients.J Pharmacol Exp Ther 1994,271(1):549-556.
27.Thummel KE,Shen DD,Podoll TD,et al.Use of midazolam as a human cytochromeP4503A probe:Ⅱ.Characterization of inter and intra individual hepatic CYP3A variability after liver transplantation.J Pharmacol Exp Ther 1994,271(1):557-566.
28.Zhu B,Ou Yang DS,Cheng ZN,et al.Single plasma sampling to predict oral clearance of CYP3A probe midazolam.Acta Pharmacol Sin 2001,22(7):634-638.
29.Villeneuve JP,L'Ecuyer L,De Maeght S,et al.Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe.Clin Pharmacol Ther 2000,67(3):242-248.
30.He P,Court MH,Greenblatt DJ,et al.Factors influencing midazolam hydroxylation activity in human liver microsomes.Drug Metab Dispos 2006,34(7):1198-1207.
31.Wolbold R,Klein K,Burk O,et al.Sex is a major determinant of CYP3A4expression in human liver.Hepatology 2003,38(4):978-988.
32.Kest B,Sarton E,Dahan A.Gender differences in opioid-mediated analgesia:animal and human studies.Anesthesiology 2000,93(2):539-547.
33.Hu YF,He J,Chen GL,et al.CYP3A5~*3 and CYP3A4~*18 single nucleotide polymorphismsin a Chinese population.Clinica Chimica Acta 2005,353(1-2): 187-192.
34.Fukushima-Uesaka H,Saito Y,Watanabe H,et al.Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotype in a Japanese population.Human Mutation 2008,26(1):100-108.
35.成碟,徐为人,刘昌孝.细胞色素P450(CYP450)遗传多态性研究进展.中国药理学通报.2006,22(12):1409-1414.
36.周宏灏,主编.遗传药理学.第1版.北京:科学出版社,2001.98-100.
37.Lamba JK,Lin YS,Schuetz EG,et al.Genetic contribution to-variable human CYP3 A-mediated metabolism.Adv Drug Deliv Rev 2002,54(10):1271-1294.
38.Sata F,Sapone A,Elizondo G,et al.CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12:evidence for an allelic variant with altered catalvtic activity.Clin Pharmacol Ther 2000,67(1):48-56.
39.Eiselt R,Domanski TL,Zibat A,et al.Identification and functional characterization of eight CYP3A4 protein variants.Pharmacogenetics 2001,11(5):447-458.
40.储小曼,曹文,闵佩清等.肾移植病人中CYP3A4基因多态性对环孢素A代谢的影响.中国临床药理学杂志.2003,19(6):421-425.
41.Chia YY,Kuo MC,Liu K,et al.Does postoperative pain induce emesis? Clin J Pain 2002,18(5):317-323.
42.Stanley G,Appadu B,Mead M,et al.Dose requirements,efficacy and side effects of morphine and pethidine delivered by patient-controlled analgesia after gynaecological surgery.Br J Anaesth 1996,76(4):484-486.
43.Pirmohamed M,Park BK.Cytochrome P450 enzyme polymorphisms and adverse drug reactions.Toxicology 2003,192(1):23-32.
1.周宏灏,主编.遗传药理学.第1版.北京:科学出版社,2001.98-100.
2.朱学慧,娄建石.细胞色素P4503A选择性探针药物的评价.中国临床药理学与治疗学.2004,9(4):365-369.
3.von Richter O,Burk O,Fromm MF,et al.Thon KP,Eichelbaum M,Kivist(o|¨) KT.Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes:a comparative analysis in paired tissue specimens.Clin Pharmacol Ther 2004,75(4):172-183.
4.舒炎,周宏灏.细胞色素P450药物氧化代谢酶的遗传药理学进展.见:王永铭,苏定冯,主编.药理学进展.第1版.北京:科学出版社,2000.19.
5.Zhu B,Liu ZQ,Chen GL,et al.The distribution and gender difference of CYP3A activity in Chinese subjects.Br J Clin Pharmacol 2003,55(3):264-269.
6.He P,Court MH,Greenblatt DJ,et al.Factors influencing midazolam hydroxylation activity in human liver microsomes.Drug Metab Dispos 2006,34(7):1198-1207.
7.Diczfalusy U,Miura J,Roh HK,et al.4Beta-hydroxycholesterol is a new endogenous CYP3A marker:relationship to CYP3A5 genotype,quinine 3-hydroxylation and sex in Koreans,Swedes and Tanzanians.Pharmacogenet Genomics 2008,18(3):201-208.
8.Wolbold R,Klein K,Burk O,et al.Sex is a major determinant of CYP3A4expression in human liver.Hepatology 2003,38(4):978-988.
9.Shimada T,Yamazaki H,Mimura M,et al.Interindividual variations in human liver cytochrome P-450 enzymes involves in the oxidation of drugs,carcinogens and toxic chemicals:studies with liver microsomes of 30 Japanese and 30Caucasians.J Pharmacol Exp Ther 1994,270(1):414-423.
10.Ashsan CH,Renwick AG,Macklin B,et al.Ethnic differences in the pharmacokinetics of oral nifedipine.Br J Clin Pharamacol 1991,31(4):399-403.
11.Gonzalez FJ,Schmid BJ,Umeno M,et al.Human P450PCN1:sequence,chromosome localization,and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase.DNA 1988,7(2):79-86.
12.Hsieh KP,Lin YY,Cheng CL,et al.Novel mutations of CYP3A4 in Chinese.Drug Metab Dispos 2001,29(3):268-273.
13.Matsumura K,Saito T,Takahashi Y,et al.Identification of a novel polymorphic enhancer of the human CYP3A4 gene.Mol Pharmacol 2004,65(4):326-334.
14.Sata F,Sapone A,Elizondo G,et al.CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12:evidence for all allelic variant with altered catalytic activity.Clin Pharmacol Ther 2000,67(1):48-56.
15.Eiselt R,Domanski TL,Zibat A,et al.Identification and functional characterization of eight CYP3A4 protein variants.Pharmacogenetics 2001,11(5):447-458.
16.Lamba JK,Lin YS,Thummel K,et al.Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.Pharmacogenetics 2002,12(2):121-132.
17.Dai D,Tang J,Rose R,et al.Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.J Pharmacol Exp Ther 2001,299(3):825-831.
18.Hu YF,He J,Chen GL,et al.CYP3A5~*3 and CYP3A4~*18 single nucleotide polymorphismsin a Chinese population.Clinica Chimica Acta 2005,353(1-2):187-192.
19.Westlind-Johnsson A,Hermann R,Huennemeyer A,et al.Identification and characterization of CYP3A4~*20,a novel rare CYP3A4 allele without functional activity.Clin Pharmacol Ther 2006,79(4):339-349.
20.Fukushima-Uesaka H,Saito Y,Watanabe H,et al.Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotype in a Japanese population.Human Mutation 2008,26(1):100-108.
21.Du J,Xing Q,Xu L,et al.Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.Pharmacogenomics 2006,7(1-2):831-841.
22.Du J,Yu L,Wang L,et al.Differences in CYP3A4~*1G genotype distribution and haplotypes of CYP3A4,CYP3A5 and CYP3A7 in 3 Chinese populations.Clin Chim Acta 2007,383(3):172-174.
23.黄敏,汪晖,平洁等.中国大陆汉族人群基因变异分析.中国临床药理学与治疗学.2006,11(3):300-304.
24.储小曼,曹文,闵佩清等.肾移植病人中CYP3A4基因多态性对环孢素A代谢的影响.中国临床药理学杂志.2003,19(6):421-425.
25. Murayama N, Nakamura T, Saeki M, et al. CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. Drug Metab Pharmacokinet 2002, 17(2): 150-156.
26. Kang YS, Park SY, Yim CH, et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 2009, 85(3):312-318.
27. Hu YF, Tu JH, Tan ZR, et al. Association of CYP3A4*18B polymorphisms with the Pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 2007, 37(3):315-327.
28. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27(4):383-391.
29. Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 2008, 64(9):877-882.
30. Projean D, Morin PE, Tu TM, et al. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica 2003, 33(8):841-854.
31. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P4503A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997, 25(9): 1072-1080.
32. Hallberg P, Marten L, Wadelius M. Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol 2006, 62(6):491 -492.
33. Tsutsumi Y, Kanamori H, Tanaka J, et al. Withdrawal symptoms from transdermal fentanyl (TDF) after an allogeneic peripheral blood stem cell transplant (PBSCT). Pain Med 2006, 7(2):164-165.
34. Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001, 298(3): 1021-1032.
35. Fritz HG, Holzmayr M, Walter B, et al. The effect of mild hypothermia on plasma fentanyl concentration and biotransformation in juvenile pigs. Anesth Analg 2005, 100(4):996-1002.
36. Baririan N, Horsmans Y, Desager JP, et al. Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. J Clin Pharmacol 2005, 45(3): 1434-1441.
37. Ibrahim AE, Feldman J, Karim A, et al. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the Pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology 2003, 98(4):853-861.
38. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006, 80(6):668-681.
39. Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf 2007, 6(3):289-303.
40. Baker JR, Best AM, Pade PA, et al. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother 2006, 40(3):392-396.
41. Bomsien S, Skopp G. An in vitro approach to potential methadone metabolic-inhibition interactions. Eur J Clin Pharmacol. 2007, 63(9):821-827.
42. Kharasch ED, Bedynek PS, Walker A, et al. Mechanism of ritonavir changes in methadone Pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.Clin Pharmacol Ther 2008, 84(4):506-512.
43. Kharasch ED, Walker A, Whittington D, et al. Methadone metabolism and clearance are induced by nelfmavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 2009, 101(3): 158-168.
44. Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state Pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19(15): 1635-1641.
45. Boffito M, Rossati A, Reynolds HE, et al. Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS Res Hum Retroviruses 2002, 18(3):341-342.
46. Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 2002, 34(3):1143-1145.
47.Calvo R,Lukas JC,Rodriguez M,et al.Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz.Br J Clin Pharmacol 2002,53(3):212-214.
48.Wang JS,DeVane CL.Involvement of CYP3A4,CYP2C8,and CYP2D6 in the metabolism of(R)- and(S)-methadone in vitro.Drug Metab Dispos 2003,31(6):742-747.
49.Weschules D J,Bain KT,Richeimer S.Actual and potential drug interactions associated with methadone.Pain Med 2008,9(3):315-344.
50.Elkader A,Sproule B.Buprenorphine:clinical pharmacokinetics in the treatment of opioid dependence.Clin Pharmacokinet 2005,44(7):661-680.
51.Umehara K,Shimokawa Y,Miyamoto G.Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.Biol Pharm Bull 2002,25(5):682-685.
52.Bomsien S,Aderjan R,Mattern R,et al.Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes.Eur J Clin Pharmacol 2006,62(9):639-643.
53.Weiss J,Sawa E,Riedel KD,et al.In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4,CYP2C19,and CYP2D6.Naunyn Schmiedebergs Arch Pharmacol 2008,378(3):275-282.
54.Curry SC,Watts DJ,Katz KD,et al.The effect of single-dose tramadol on oxycodone clearance.J Emerg Med 2007,33(4):407-411.
55.Lee HK,Lewis LD,Tsongalis GJ,et al.Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism.Clin Chim Acta 2006,367(1-2):196-200.
56.Chamberlin KW,Cottle M,Neville R,et al.Oral oxymorphone for pain management.Ann Pharmacother 2007,41(7):1144-1152.
57.周宏灏,基因多态性与临床合理用药.中华医学杂志,2000,80(3):658-661.
58.Jin M,Gock SB,Jannetto PJ,et al.Pharmacogenomics as molecular autopsy for forensic toxicology:genotyping cytochrome P450 3A4~*1B and 3A5~*3 for 25fentanyl cases.J Anal Toxicol 2005,29(7):590-598.
2. Apfelbaum JL, Chen C, Mehta SS, et al. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg 2003, 97(2):534-540.
3. Dolin SJ, Cashman JN, Bland JM. Effectiveness of acute postoperative pain management: I. Evidence from published data. Br J Anaesth 2002, 89(3):409-423.
4. Bisgaard T, Klarskov B, Rosenberg J, et al. Characteristics and prediction of early pain after laparoscopic cholecystectomy. Pain 2001, 90(3):261-269.
5. Cepeda MS, Carr DB. Women experience more pain and require more morphine than men to achieve a similar degree of analgesia. Anesth Analg 2003, 97(5): 1464-1468.
6. Tan EC, Lim Y, Teo YY, et al. Ethnic differences in pain perception and patient-controlled analgesia usage for postoperative pain. J Pain 2008, 9(9):849-855.
7. Lotsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005, 11(2):82-89.
8. Nagashima M, Katoh R, Sato Y, et al. Is there genetic polymorphism evidence for individual human sensitivity to opiates? Curr Pain Headache Rep 2007, 11(2):115-123.
9. Abood ME. Molecular biology of cannabinoid receptors. Handb Exp Pharmacol 2005, (168):81-115.
10. Samer CF, Piguet V, Dayer P, et al. Genetic polymorphism and drug interactions: their importance in the treatment of pain. Can J Anaesth 2005, 52(8):806-821.
11. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P4503A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997,25(9):1072-1080.
12.舒炎,周宏灏.细胞色素P450药物氧化代谢酶的遗传药理学进展.见:王永铭,苏定冯,主编.药理学进展.第1版.北京:科学出版社,2000.19.
13.Zhu B,Liu ZQ,Chen GL,et al.The distribution and gender difference of CYP3A activity in Chinese subjects.Br J Clin Pharmacol 2003,55(3):264-269.
14.Ozdemir V,Kalow W,Tang BK,et al.Evaluation of the genetic component of variability in CYP3A4 activity:a repeated drug administration method.Pharmacogenetics 2000,10(5):373-388.
15.Hsieh KP,Lin YY,Cheng CL,et al.Novel mutations of CYP3A4 in Chinese.Drug Metab Dispos 2001,29(3):268-273.
16.Dai D,Tang J,Rose R,et al.Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.J Pharmacol Exp Ther 2001,299(3):825-831.
17.Du J,Xing Q,Xu L,et al.Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.Pharmacogenomics 2006,7(6):831-841
18.Du J,Yu L,Wang L,et al.Differences in CYP3A4~*1G genotype distribution and haplotypes of CYP3A4,CYP3A5 and CYP3A7 in 3 Chinese populations.Clin Chim Acta 2007,383(1-2):172-174.
19.Hu YF,Tu JH,Tan ZR,et al.Association of CYP3A4~*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects.Xenobiotica 2007,37(3):315-327.
20.Gao Y,Zhang LR,Fu Q.CYP3A4~*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.Eur J Clin Pharmacol 2008,64(9):877-882.
21.Kharasch ED,Thummel KE,Watkins PB.CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition.Mol Interv 2005,5(2):151-153.
22.Camu F,Van Aken H,Bovill JG,et al.Postoperative analgesic effects of three demand-dose sizes of fentanyl administered by patient-controlled analgesia.Anesth Analg 1998,87(4):890-895.
23.Sommer M,de Rijke JM,van Kleef M,et al.The prevalence of postoperative pain in a sample of 1490 surgical inpatients.Eur J Anaesthesiol 2008,25(4):267-274.
24.朱学慧,娄建石.细胞色素P4503A选择性探针药物的评价.中国临床药理学与治疗学.2004,9(4):365-369.
25.Lown KS,Kolars JC,Thummel KE,et al.Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel.Lack of prediction by the erythromycin breath test.Drug Metab Dispos 1994,22(6):947-955.
26.Thummel KE,Shen DD,Podoll TD,et al.Use of midazolam as a human cytochromeP4503Aprobe:Ⅰ.In vitro-in vivo correlations in liver transplant patients.J Pharmacol Exp Ther 1994,271(1):549-556.
27.Thummel KE,Shen DD,Podoll TD,et al.Use of midazolam as a human cytochromeP4503A probe:Ⅱ.Characterization of inter and intra individual hepatic CYP3A variability after liver transplantation.J Pharmacol Exp Ther 1994,271(1):557-566.
28.Zhu B,Ou Yang DS,Cheng ZN,et al.Single plasma sampling to predict oral clearance of CYP3A probe midazolam.Acta Pharmacol Sin 2001,22(7):634-638.
29.Villeneuve JP,L'Ecuyer L,De Maeght S,et al.Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe.Clin Pharmacol Ther 2000,67(3):242-248.
30.He P,Court MH,Greenblatt DJ,et al.Factors influencing midazolam hydroxylation activity in human liver microsomes.Drug Metab Dispos 2006,34(7):1198-1207.
31.Wolbold R,Klein K,Burk O,et al.Sex is a major determinant of CYP3A4expression in human liver.Hepatology 2003,38(4):978-988.
32.Kest B,Sarton E,Dahan A.Gender differences in opioid-mediated analgesia:animal and human studies.Anesthesiology 2000,93(2):539-547.
33.Hu YF,He J,Chen GL,et al.CYP3A5~*3 and CYP3A4~*18 single nucleotide polymorphismsin a Chinese population.Clinica Chimica Acta 2005,353(1-2): 187-192.
34.Fukushima-Uesaka H,Saito Y,Watanabe H,et al.Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotype in a Japanese population.Human Mutation 2008,26(1):100-108.
35.成碟,徐为人,刘昌孝.细胞色素P450(CYP450)遗传多态性研究进展.中国药理学通报.2006,22(12):1409-1414.
36.周宏灏,主编.遗传药理学.第1版.北京:科学出版社,2001.98-100.
37.Lamba JK,Lin YS,Schuetz EG,et al.Genetic contribution to-variable human CYP3 A-mediated metabolism.Adv Drug Deliv Rev 2002,54(10):1271-1294.
38.Sata F,Sapone A,Elizondo G,et al.CYP3A4 allelic variants with amino acid substitutions in exon 7 and 12:evidence for an allelic variant with altered catalvtic activity.Clin Pharmacol Ther 2000,67(1):48-56.
39.Eiselt R,Domanski TL,Zibat A,et al.Identification and functional characterization of eight CYP3A4 protein variants.Pharmacogenetics 2001,11(5):447-458.
40.储小曼,曹文,闵佩清等.肾移植病人中CYP3A4基因多态性对环孢素A代谢的影响.中国临床药理学杂志.2003,19(6):421-425.
41.Chia YY,Kuo MC,Liu K,et al.Does postoperative pain induce emesis? Clin J Pain 2002,18(5):317-323.
42.Stanley G,Appadu B,Mead M,et al.Dose requirements,efficacy and side effects of morphine and pethidine delivered by patient-controlled analgesia after gynaecological surgery.Br J Anaesth 1996,76(4):484-486.
43.Pirmohamed M,Park BK.Cytochrome P450 enzyme polymorphisms and adverse drug reactions.Toxicology 2003,192(1):23-32.
1.周宏灏,主编.遗传药理学.第1版.北京:科学出版社,2001.98-100.
2.朱学慧,娄建石.细胞色素P4503A选择性探针药物的评价.中国临床药理学与治疗学.2004,9(4):365-369.
3.von Richter O,Burk O,Fromm MF,et al.Thon KP,Eichelbaum M,Kivist(o|¨) KT.Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes:a comparative analysis in paired tissue specimens.Clin Pharmacol Ther 2004,75(4):172-183.
4.舒炎,周宏灏.细胞色素P450药物氧化代谢酶的遗传药理学进展.见:王永铭,苏定冯,主编.药理学进展.第1版.北京:科学出版社,2000.19.
5.Zhu B,Liu ZQ,Chen GL,et al.The distribution and gender difference of CYP3A activity in Chinese subjects.Br J Clin Pharmacol 2003,55(3):264-269.
6.He P,Court MH,Greenblatt DJ,et al.Factors influencing midazolam hydroxylation activity in human liver microsomes.Drug Metab Dispos 2006,34(7):1198-1207.
7.Diczfalusy U,Miura J,Roh HK,et al.4Beta-hydroxycholesterol is a new endogenous CYP3A marker:relationship to CYP3A5 genotype,quinine 3-hydroxylation and sex in Koreans,Swedes and Tanzanians.Pharmacogenet Genomics 2008,18(3):201-208.
8.Wolbold R,Klein K,Burk O,et al.Sex is a major determinant of CYP3A4expression in human liver.Hepatology 2003,38(4):978-988.
9.Shimada T,Yamazaki H,Mimura M,et al.Interindividual variations in human liver cytochrome P-450 enzymes involves in the oxidation of drugs,carcinogens and toxic chemicals:studies with liver microsomes of 30 Japanese and 30Caucasians.J Pharmacol Exp Ther 1994,270(1):414-423.
10.Ashsan CH,Renwick AG,Macklin B,et al.Ethnic differences in the pharmacokinetics of oral nifedipine.Br J Clin Pharamacol 1991,31(4):399-403.
11.Gonzalez FJ,Schmid BJ,Umeno M,et al.Human P450PCN1:sequence,chromosome localization,and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase.DNA 1988,7(2):79-86.
12.Hsieh KP,Lin YY,Cheng CL,et al.Novel mutations of CYP3A4 in Chinese.Drug Metab Dispos 2001,29(3):268-273.
13.Matsumura K,Saito T,Takahashi Y,et al.Identification of a novel polymorphic enhancer of the human CYP3A4 gene.Mol Pharmacol 2004,65(4):326-334.
14.Sata F,Sapone A,Elizondo G,et al.CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12:evidence for all allelic variant with altered catalytic activity.Clin Pharmacol Ther 2000,67(1):48-56.
15.Eiselt R,Domanski TL,Zibat A,et al.Identification and functional characterization of eight CYP3A4 protein variants.Pharmacogenetics 2001,11(5):447-458.
16.Lamba JK,Lin YS,Thummel K,et al.Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.Pharmacogenetics 2002,12(2):121-132.
17.Dai D,Tang J,Rose R,et al.Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.J Pharmacol Exp Ther 2001,299(3):825-831.
18.Hu YF,He J,Chen GL,et al.CYP3A5~*3 and CYP3A4~*18 single nucleotide polymorphismsin a Chinese population.Clinica Chimica Acta 2005,353(1-2):187-192.
19.Westlind-Johnsson A,Hermann R,Huennemeyer A,et al.Identification and characterization of CYP3A4~*20,a novel rare CYP3A4 allele without functional activity.Clin Pharmacol Ther 2006,79(4):339-349.
20.Fukushima-Uesaka H,Saito Y,Watanabe H,et al.Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotype in a Japanese population.Human Mutation 2008,26(1):100-108.
21.Du J,Xing Q,Xu L,et al.Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.Pharmacogenomics 2006,7(1-2):831-841.
22.Du J,Yu L,Wang L,et al.Differences in CYP3A4~*1G genotype distribution and haplotypes of CYP3A4,CYP3A5 and CYP3A7 in 3 Chinese populations.Clin Chim Acta 2007,383(3):172-174.
23.黄敏,汪晖,平洁等.中国大陆汉族人群基因变异分析.中国临床药理学与治疗学.2006,11(3):300-304.
24.储小曼,曹文,闵佩清等.肾移植病人中CYP3A4基因多态性对环孢素A代谢的影响.中国临床药理学杂志.2003,19(6):421-425.
25. Murayama N, Nakamura T, Saeki M, et al. CYP3A4 gene polymorphisms influence testosterone 6beta-hydroxylation. Drug Metab Pharmacokinet 2002, 17(2): 150-156.
26. Kang YS, Park SY, Yim CH, et al. The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 2009, 85(3):312-318.
27. Hu YF, Tu JH, Tan ZR, et al. Association of CYP3A4*18B polymorphisms with the Pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 2007, 37(3):315-327.
28. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27(4):383-391.
29. Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 2008, 64(9):877-882.
30. Projean D, Morin PE, Tu TM, et al. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica 2003, 33(8):841-854.
31. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P4503A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997, 25(9): 1072-1080.
32. Hallberg P, Marten L, Wadelius M. Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol 2006, 62(6):491 -492.
33. Tsutsumi Y, Kanamori H, Tanaka J, et al. Withdrawal symptoms from transdermal fentanyl (TDF) after an allogeneic peripheral blood stem cell transplant (PBSCT). Pain Med 2006, 7(2):164-165.
34. Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001, 298(3): 1021-1032.
35. Fritz HG, Holzmayr M, Walter B, et al. The effect of mild hypothermia on plasma fentanyl concentration and biotransformation in juvenile pigs. Anesth Analg 2005, 100(4):996-1002.
36. Baririan N, Horsmans Y, Desager JP, et al. Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions. J Clin Pharmacol 2005, 45(3): 1434-1441.
37. Ibrahim AE, Feldman J, Karim A, et al. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the Pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology 2003, 98(4):853-861.
38. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006, 80(6):668-681.
39. Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf 2007, 6(3):289-303.
40. Baker JR, Best AM, Pade PA, et al. Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother 2006, 40(3):392-396.
41. Bomsien S, Skopp G. An in vitro approach to potential methadone metabolic-inhibition interactions. Eur J Clin Pharmacol. 2007, 63(9):821-827.
42. Kharasch ED, Bedynek PS, Walker A, et al. Mechanism of ritonavir changes in methadone Pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.Clin Pharmacol Ther 2008, 84(4):506-512.
43. Kharasch ED, Walker A, Whittington D, et al. Methadone metabolism and clearance are induced by nelfmavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 2009, 101(3): 158-168.
44. Friedland G, Andrews L, Schreibman T, et al. Lack of an effect of atazanavir on steady-state Pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS 2005, 19(15): 1635-1641.
45. Boffito M, Rossati A, Reynolds HE, et al. Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. AIDS Res Hum Retroviruses 2002, 18(3):341-342.
46. Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 2002, 34(3):1143-1145.
47.Calvo R,Lukas JC,Rodriguez M,et al.Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz.Br J Clin Pharmacol 2002,53(3):212-214.
48.Wang JS,DeVane CL.Involvement of CYP3A4,CYP2C8,and CYP2D6 in the metabolism of(R)- and(S)-methadone in vitro.Drug Metab Dispos 2003,31(6):742-747.
49.Weschules D J,Bain KT,Richeimer S.Actual and potential drug interactions associated with methadone.Pain Med 2008,9(3):315-344.
50.Elkader A,Sproule B.Buprenorphine:clinical pharmacokinetics in the treatment of opioid dependence.Clin Pharmacokinet 2005,44(7):661-680.
51.Umehara K,Shimokawa Y,Miyamoto G.Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.Biol Pharm Bull 2002,25(5):682-685.
52.Bomsien S,Aderjan R,Mattern R,et al.Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes.Eur J Clin Pharmacol 2006,62(9):639-643.
53.Weiss J,Sawa E,Riedel KD,et al.In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4,CYP2C19,and CYP2D6.Naunyn Schmiedebergs Arch Pharmacol 2008,378(3):275-282.
54.Curry SC,Watts DJ,Katz KD,et al.The effect of single-dose tramadol on oxycodone clearance.J Emerg Med 2007,33(4):407-411.
55.Lee HK,Lewis LD,Tsongalis GJ,et al.Negative urine opioid screening caused by rifampin-mediated induction of oxycodone hepatic metabolism.Clin Chim Acta 2006,367(1-2):196-200.
56.Chamberlin KW,Cottle M,Neville R,et al.Oral oxymorphone for pain management.Ann Pharmacother 2007,41(7):1144-1152.
57.周宏灏,基因多态性与临床合理用药.中华医学杂志,2000,80(3):658-661.
58.Jin M,Gock SB,Jannetto PJ,et al.Pharmacogenomics as molecular autopsy for forensic toxicology:genotyping cytochrome P450 3A4~*1B and 3A5~*3 for 25fentanyl cases.J Anal Toxicol 2005,29(7):590-598.